Sei sulla pagina 1di 4
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AVENTIS PHARMA S.A., SANOFI-AVENTIS U.S., LLC Plaintiffs, v. C.A. No. 07-721-GMS HOSPIRA, INC., Defendant, AVENTIS PHARMA S.A., SANOFI-AVENTIS U.S., LLC Plaintiffs, v. C.A. No. 08-496-GMS APOTEX, INC., APOTEX CORP., AMENDED ORDER CONSTRUING THE TERMS OF. U.S. PATENT NOS. 5,714,512; 5,750,561; AND 5.698.582 After having considered the submissions of the parties and hearing oral argument on the matter, IT IS HEREBY ORDERED, ADJUDGED, and DECREED that, as used in the asserted claims of U.S. Patent Nos. 5,714,512 (the “*512 patent”), 5,750,561 (the “*561 patent”), and 5,698,582 (the “*582 patent”): A. ‘The ‘512 Patent 1 ‘The term “stock solution” in claim 33 of the ‘512 patent is construed to mean “a concentrated solution. ' The court adopts a construction that is consistent with the plain and ordinary meaning of the term and that gives effect to each term of the claim. See, e.g.. In re Gabapentin Patent Lit., 2. The term “essentially free or free of ethanol” in claim 7 of the ‘512 patent is construed to mean: ” and (a) Fora stock solution, “no more than 5% ethanol by volume, (b) For a perfusion, “the same amount of ethanol as a stock solution with no more than 5% ethanol by volume.” 3. The term “dissolved” in claim 7 of the ‘512 patent is construed to have its plain and ordinary meaning.* 4. Claims 24 through 35 of the ‘512 patent are construed so as not to include the limitation “essentially free or free of ethanol.”* B. The ‘S61 Patent 1. The term “dissolved” in claims 2 and 10 of the ‘S61patent is construed to have its plain and ordinary meani 2. The term “consisting essentially of” in claims 2;-5; and 10 of the ‘561 patent is 503 F.3d 1254, 1263 (Fed. Cir.2007) (noting that “claims are interpreted with an eye towards giving effect to all terms in a claim”). ? There is no dispute as to the construction of this term for a “stock solution.” (D.I. 42 at 1.44 at 3.) The court rejects the plaintiffs’ proposed construction. The plaintiffs" proposed construction is not supported by the patent specification or the prosecution history. * The court rejects Apotex’s proposed construction. See footnote 1. * The court rejects Hospira’s proposed limitations on these claims. See Serrano v. Telular Corp., 111 F.3d 1578, 1584 (Fed. Cir. 1997) (“Although statements in file history may of course be used to explain and potentially limit the meaning of claim limitations, . ..{they] cannot be used to add an entirely new limitation to a claim.”) ° See footnote 4. construed to mean “composed of the listed ingredients, and may include other ingredients that do not affect the bas and novel properties of the invention.”? 3 The term “which contains” in claim 5 of the ‘S61 patent is construed to mean “comprising.”* 4. Theterm“Taxotere” in claim 10 of the ‘$61 patent is construed to mean the chemical compound known as docetaxel.” 5. The term “capable of being injected without anaphylactic or alcohol intoxication manifestation” in claims 2 and 5 of the ‘561 patent is construed to mean “having reasonable expectation of being injected without causing anaphylactic or aleohol intoxication manifestation.”"” The ‘582 Patent 1. The term “dissolved” in claim 1 of the ‘S82 patent is construed to have its plain and ordinary meaning, ” The court adopts a construction that is consistent with the established meaning of this, term. See, e.g., PPG Indus. v. Guardian indus. Corp., 156 F.3d 1351, 1354 (Fed. Cir. 1998) (construing the term “consisting essentially of” to mean that the “invention necessarily includes the listed ingredients and is open to unlisted ingredients that do not materially affect the basic and novel properties of the invention”). The listing of claim 5 in this paragraph in the original version of this order (D.I. 153) was a typographical error. The term “consisting essentially of” does not appear in claim 5 of the ‘561 patent. Thus, this paragraph of the order applies only to claims 2 and 10 of the ‘S61 patent, * The court rejects Hospira’s proposed construction. See Mars, Inc. v. H.J. Heinz Co., L.P.,377 F.3d 1369, 1375-77 (Fed. Cir. 2004) (noting that “which contains” is an open-ended ‘erm synonymous with “comprising” or “including” and does not exclude “additional, unnamed ingredients”), ° The court adopts the plaintiff's’ construction and rejects Apotex’s proposed construction. '° The court rejects Apotex’s proposed construction. See footnote 1. 3

Potrebbero piacerti anche

  • Pfizer v. Teva (09-307)
    Pfizer v. Teva (09-307)
    Documento1 pagina
    Pfizer v. Teva (09-307)
    YCSTBlog
    Nessuna valutazione finora
  • Kenexa Brassring Inc. v. Taleo Corp., C.A. No. 07-521-SLR (D. Del. Nov. 18, 2010) (Robinson, J.) .
    Kenexa Brassring Inc. v. Taleo Corp., C.A. No. 07-521-SLR (D. Del. Nov. 18, 2010) (Robinson, J.) .
    Documento3 pagine
    Kenexa Brassring Inc. v. Taleo Corp., C.A. No. 07-521-SLR (D. Del. Nov. 18, 2010) (Robinson, J.) .
    YCSTBlog
    Nessuna valutazione finora
  • 09 26
    09 26
    Documento4 pagine
    09 26
    YCSTBlog
    Nessuna valutazione finora
  • 08 408
    08 408
    Documento5 pagine
    08 408
    YCSTBlog
    Nessuna valutazione finora
  • 06 105
    06 105
    Documento3 pagine
    06 105
    YCSTBlog
    Nessuna valutazione finora
  • 07 331
    07 331
    Documento20 pagine
    07 331
    YCSTBlog
    Nessuna valutazione finora
  • Ampex Kodak
    Ampex Kodak
    Documento42 pagine
    Ampex Kodak
    YCSTBlog
    Nessuna valutazione finora
  • Bone Care International LLC v. Sandoz Inc., C.A. No. 09-524-GMS (D. Del. Sep. 30, 2010
    Bone Care International LLC v. Sandoz Inc., C.A. No. 09-524-GMS (D. Del. Sep. 30, 2010
    Documento2 pagine
    Bone Care International LLC v. Sandoz Inc., C.A. No. 09-524-GMS (D. Del. Sep. 30, 2010
    YCSTBlog
    Nessuna valutazione finora
  • 06 495
    06 495
    Documento2 pagine
    06 495
    YCSTBlog
    Nessuna valutazione finora
  • Diode
    Diode
    Documento2 pagine
    Diode
    YCSTBlog
    Nessuna valutazione finora
  • 09 484
    09 484
    Documento13 pagine
    09 484
    YCSTBlog
    Nessuna valutazione finora
  • Documento10 pagine
    YCSTBlog
    Nessuna valutazione finora
  • 08 290
    08 290
    Documento1 pagina
    08 290
    YCSTBlog
    Nessuna valutazione finora
  • 08 234
    08 234
    Documento3 pagine
    08 234
    YCSTBlog
    Nessuna valutazione finora
  • 09 072
    09 072
    Documento2 pagine
    09 072
    YCSTBlog
    Nessuna valutazione finora
  • Smith Kline
    Smith Kline
    Documento1 pagina
    Smith Kline
    YCSTBlog
    Nessuna valutazione finora
  • Hesco
    Hesco
    Documento5 pagine
    Hesco
    YCSTBlog
    Nessuna valutazione finora
  • Girafa
    Girafa
    Documento6 pagine
    Girafa
    YCSTBlog
    Nessuna valutazione finora
  • Forest
    Forest
    Documento10 pagine
    Forest
    YCSTBlog
    Nessuna valutazione finora
  • Documento5 pagine
    YCSTBlog
    Nessuna valutazione finora
  • 07 787a
    07 787a
    Documento6 pagine
    07 787a
    YCSTBlog
    Nessuna valutazione finora
  • 06 187
    06 187
    Documento5 pagine
    06 187
    YCSTBlog
    Nessuna valutazione finora
  • Documento67 pagine
    YCSTBlog
    Nessuna valutazione finora
  • Documento22 pagine
    YCSTBlog
    Nessuna valutazione finora
  • 07 787a
    07 787a
    Documento6 pagine
    07 787a
    YCSTBlog
    Nessuna valutazione finora
  • Documento61 pagine
    YCSTBlog
    Nessuna valutazione finora
  • Documento29 pagine
    YCSTBlog
    Nessuna valutazione finora
  • Documento3 pagine
    YCSTBlog
    Nessuna valutazione finora
  • 07 787a
    07 787a
    Documento6 pagine
    07 787a
    YCSTBlog
    Nessuna valutazione finora